OHSU in the news

Study brings substance abuse support to Wallowa County

The La Grande Observer November 17, 2025
OHSU’s Rural Practice-based Research Network is collaborating with Winding Waters Clinics in Enterprise, Oregon, on a national study, called Co-Care, that supports primary care clinicians and their patients with a team of nurse care managers and health coaches with a goal of lowering patients’ use of alcohol and other substances.

Inside the VA’s Hub-and-Spoke Model for Multiple Sclerosis Care: Rebecca Spain, MD

American Journal of Managed Care November 15, 2025
Rebecca Spain, M.D., discusses how the Department of Veterans Affairs Multiple Sclerosis Centers of Excellence operate as a nationwide hub-and-spoke network designed to ensure every veteran with multiple sclerosis has access to specialized, multidisciplinary care wherever they live.

Evolving Our Understanding of Cancer’s Evolution, Progression, and Persistence

American Association for Cancer Research November 14, 2025
Lara Heiser, Ph.D., who chairs the American Association for Cancer Research’s Cancer Evolution Working Group, successfully advocated for the AACR to host a special conference in December to explore the evolution principles of cancer from its initiation to relapse; Heiser says: “The CEWG has been quite active in building a community of researchers to promote the integration of evolutionary principles of cancer into all areas of cancer research, and bringing those ideas to the broader AACR community."

OHSU Prez Rings “Alarm Bell” Over Changes to Federal Drug Discount Program

Willamette Week November 14, 2025
At his monthly media availability, Shereef Elnahal, M.D., voices concern about potential cuts to the 340-B program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients.

FDA approves 100th small-molecule kinase inhibitor

Nature November 13, 2025
In the late 1980s Brian Druker, M.D., theorized that kinase inhibitors could be transformative for cancer care; specifically, that a small molecule could block the activated kinase that characterizes chronic myeloid leukemia. In 1996 he and a colleague reported that the small molecule, their agent, wiped out cancer-causing CML cells in preclinical models. This finding sparked decades of kinase inhibitor research. Recently, the FDA recently approved the 100th small-molecule kinase inhibitor, and drug makers and scientists continue to mine kinases for potential drug targets.
See more stories